Editorial comment on: Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor.
Pinthus
Jehonathan
J
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002465:Cell Movement / Q000187:drug effects*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D059648:Kisspeptins; D061965:Matrix Metalloproteinase Inhibitors; D008967:Molecular Biology / Q000379:methods; D009361:Neoplasm Invasiveness; D011758:Pyrroles / Q000627:therapeutic use; D043562:Receptors, G-Protein-Coupled / Q000235:genetics*; D000074502:Receptors, Kisspeptin-1; D000077210:Sunitinib; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D007211:Indoles; C106628:KISS1 protein, human; C118688:KISS1R protein, human; D059648:Kisspeptins; D061965:Matrix Metalloproteinase Inhibitors; D011758:Pyrroles; D043562:Receptors, G-Protein-Coupled; D000074502:Receptors, Kisspeptin-1; D025521:Tumor Suppressor Proteins; D000077210:Sunitinib